After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
South Korean biotech Alteogen saw its shares rise 6.3% to 381,00 won, after it announced an exclusive license agreement with ...
Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of ...
On 20 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
Alteogen said on the 25th that it signed an exclusive license agreement with Biogen, a U.S. pharmaceutical company, to develop and commercialize subcutaneous injection (SC) formulation biologics based ...
Denali Therapeutics, Inc. DNLI secured a major regulatory win with the FDA approval of lead pipeline candidate tividenofusp ...
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark ...
Amidst a backdrop of heightened geopolitical tensions, persistent inflation concerns, and volatile oil prices, global markets ...
Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
O'Neil Global Advisors Chief Investment Officer Randy Watts tells Reuters' Fred Katayama why he thinks Biogen shares aren't that pricey over the long term despite their 38% runup Monday on news of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results